REGISTER FOR THIS EVENT
6th June 2025, 13:15 - 14:00 GMT | To be held virtually
For UK & Ireland healthcare professionals only. This promotional virtual meeting has been funded and organised by Alnylam® Pharmaceuticals.
Please note that some of the sessions will include data specific to products from Alnylam Pharmaceuticals.
AMVUTTRA and ONPATTRO are indicated for indicated for the treatment of hereditary transthyretin-mediated
amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
The Overlap in hATTR-PN: Recognising and Managing Polyneuropathy with Cardiac Manifestations
Please see below for the agenda topics.
Meeting introduction:
Dr Carol Whelan, National Amyloidosis Centre, Royal Free Hospital
Dr Stephen Keddie, Barts Health NHS Trust, Royal London & Newham Hospital
The red flags of hATTR and identifying the mixed patient phenotype
Dr Carol Whelan, Consultant Cardiologist and Clinical Lead for Heart Failure
National Amyloidosis Centre, Royal Free Hospital
Neurology Perspective:
Dr Stephen Keddie, Neurology Consultant
Barts Health NHS Trust, Royal London & Newham Hospital
Q&A with Speakers
Register for this event below:
If you have already registered, please join below:
To report an adverse event in the UK:
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard/mhra.gov.uk/ or via the Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Alnylam Pharmaceuticals at 0800 141 2569 (+44 1628 878 592) or medinfo@alnylam.com
To report an adverse event in Ireland:
Adverse events should be reported. Reporting forms and information can be found at HPRA Pharmacovigilance, Website: https://www.hpra.ie/homepage/about-us/report-an-issue/human-adverse-reaction-form. Adverse events should also be reported to Alnylam Netherlands B.V. at 1800 924260 (+353 818882213) or medinfo@alnylam.com